Cargando…

Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand

BACKGROUND: Androgen deprivation therapy (ADT) administered as a prostate cancer treatment is known to exert multiple side effects including bone deterioration leading to bone fracture. The current analysis is to evaluate the burden of fracture risk in the New Zealand prostate cancer (PCa) populatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Alice, Obertová, Zuzana, Brown, Charis, Karunasinghe, Nishi, Bishop, Karen, Ferguson, Lynnette, Lawrenson, Ross
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631090/ https://www.ncbi.nlm.nih.gov/pubmed/26525985 http://dx.doi.org/10.1186/s12885-015-1843-3

Ejemplares similares

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer
por: Lawrenson, Ross, et al.
Publicado: (2014)

Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study
por: Wang, Alice, et al.
Publicado: (2017)

Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand
por: Obertová, Zuzana, et al.
Publicado: (2014)

A pilot study to investigate if New Zealand men with prostate cancer benefit from a Mediterranean-style diet
por: Erdrich, Sharon, et al.
Publicado: (2015)

Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
por: Wang, Alice, et al.
Publicado: (2021)

Selenium Supplementation and Prostate Health in a New Zealand Cohort
por: Karunasinghe, Nishi, et al.
Publicado: (2019)

An examination of clinical differences between carriers and non-carriers of chromosome 8q24 risk alleles in a New Zealand Caucasian population with prostate cancer
por: Bishop, Karen S., et al.
Publicado: (2016)

An Investigation into the Association between DNA Damage and Dietary Fatty Acid in Men with Prostate Cancer
por: Bishop, Karen S., et al.
Publicado: (2015)

Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
por: Karunasinghe, Nishi, et al.
Publicado: (2016)

Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand
por: Karunasinghe, Nishi, et al.
Publicado: (2019)

Selenium, Selenoprotein Genes and Crohn’s Disease in a Case-Control Population from Auckland, New Zealand
por: Gentschew, Liljana, et al.
Publicado: (2012)

Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts
por: Karunasinghe, Nishi, et al.
Publicado: (2018)

Nutrigenetics, Nutrigenomics, and Selenium
por: Ferguson, Lynnette R., et al.
Publicado: (2011)

Evidence of High Mortality and Increasing Burden of Sepsis in a Regional Sample of the New Zealand Population
por: Huggan, Paul J, et al.
Publicado: (2017)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
por: Neubecker, Katherine, et al.
Publicado: (2011)

Benefits of Selenium Supplementation on Leukocyte DNA Integrity Interact with Dietary Micronutrients: A Short Communication
por: Karunasinghe, Nishi, et al.
Publicado: (2016)

Prostate Cancer: Is It a Battle Lost to Age?
por: Vaidyanathan, Venkatesh, et al.
Publicado: (2016)

SNP-SNP interactions as risk factors for aggressive prostate cancer
por: Vaidyanathan, Venkatesh, et al.
Publicado: (2017)

Urban Rural Differences in Breast Cancer in New Zealand
por: Lawrenson, Ross, et al.
Publicado: (2016)

Corrigendum to “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy”
por: Neubecker, Katherine, et al.
Publicado: (2017)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma
por: Lee, Chi-Ho, et al.
Publicado: (2017)

Androgen deprivation and SARS-CoV-2 in men with prostate cancer
por: Koskinen, M., et al.
Publicado: (2020)

Cancer-preventive Properties of an Anthocyanin-enriched Sweet Potato in the APC(MIN) Mouse Model
por: Asadi, Khalid, et al.
Publicado: (2017)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
por: Morrison, Belinda F, et al.
Publicado: (2011)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
por: Gagliano-Jucá, Thiago, et al.
Publicado: (2018)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
por: Shah, Neil J, et al.
Publicado: (2022)

Zinc in Prostate Health and Disease: A Mini Review
por: Karunasinghe, Nishi
Publicado: (2022)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Are We Eating Our Way to Prostate Cancer—A Hypothesis Based on the Evolution, Bioaccumulation, and Interspecific Transfer of miR-150
por: Vaidyanathan, Venkatesh, et al.
Publicado: (2016)

High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer
por: van Oostwaard, Marsha M., et al.
Publicado: (2022)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
por: Nguyen, Paul L., et al.
Publicado: (2015)

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
por: Jayadevappa, Ravishankar, et al.
Publicado: (2019)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Two Elderly Men with Myasthenia Gravis during Androgen Deprivation Therapy for Prostate Cancer
por: Kanazawa, Kazo, et al.
Publicado: (2023)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sddr410ld1ltkari08le933sfv